These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33073261)

  • 1. Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.
    Torka P; Mavis C; Kothari S; Belliotti S; Gu J; Sundaram S; Barth M; Hernandez-Ilizaliturri FJ
    EJHaem; 2020 Jul; 1(1):122-132. PubMed ID: 33073261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
    Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
    Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
    Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
    Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
    Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
    Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Torka P; Thiruvengadam SK; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
    Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
    Paiva C; Godbersen JC; Rowland T; Danilova OV; Danes C; Berger A; Danilov AV
    Oncotarget; 2017 Mar; 8(13):21128-21139. PubMed ID: 28177892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
    Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
    Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
    Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
    Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
    Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
    Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
    Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
    Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Thiruvengadam SK; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
    Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.
    Wolenski FS; Fisher CD; Sano T; Wyllie SD; Cicia LA; Gallacher MJ; Baker RA; Kirby PJ; Senn JJ
    Cell Death Discov; 2015; 1():15034. PubMed ID: 27551465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
    O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
    Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.
    Zheng S; Leclerc GM; Li B; Swords RT; Barredo JC
    Oncotarget; 2018 Jan; 9(5):5529-5544. PubMed ID: 29464016
    [No Abstract]   [Full Text] [Related]  

  • 20. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
    Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.